These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30617953)

  • 21. The impact of rarity in NICE's health technology appraisals.
    Clarke S; Ellis M; Brownrigg J
    Orphanet J Rare Dis; 2021 May; 16(1):218. PubMed ID: 33985575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
    Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
    Kaltenthaler E; Papaioannou D; Boland A; Dickson R
    Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process.
    Carroll C; Kaltenthaler E; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
    Value Health; 2017 Jun; 20(6):785-791. PubMed ID: 28577696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Armstrong N; Ramaekers BLT; Pouwels X; Lang S; Petersohn S; Riemsma R; Worthy G; Stirk L; Ross J; Kleijnen J; Joore MA
    Pharmacoeconomics; 2019 May; 37(5):655-667. PubMed ID: 30293207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
    Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
    Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence.
    Hinde S; Wade R; Palmer S; Woolacott N; Spackman E
    Pharmacoeconomics; 2016 Jun; 34(6):587-96. PubMed ID: 26820148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process.
    Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
    Pharmacoecon Open; 2017 Jun; 1(2):99-108. PubMed ID: 29442332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Squires H; Hock E; Kaltenthaler E; Rawdin A; Alifrangis C
    Pharmacoeconomics; 2019 Sep; 37(9):1073-1080. PubMed ID: 30547369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.
    Hale G; Morris J; Barker-Yip J
    J Comp Eff Res; 2023 Nov; 12(11):e230093. PubMed ID: 37724717
    [No Abstract]   [Full Text] [Related]  

  • 34. Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A; Pollard D; Chico T; Henderson R; Stevenson M
    Pharmacoeconomics; 2016 May; 34(5):463-77. PubMed ID: 26689783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Review of Economic Models Submitted to NICE's Technology Appraisal Programme, for Treatments of T1DM & T2DM.
    Daly MJ; Elvidge J; Chantler T; Dawoud D
    Front Pharmacol; 2022; 13():887298. PubMed ID: 35645790
    [No Abstract]   [Full Text] [Related]  

  • 36. Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Whyte S; Gomersall T; Ren S; Wong R; Chambers D; Tappenden P
    Pharmacoeconomics; 2017 Jul; 35(7):717-726. PubMed ID: 27943135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
    Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.